A Preoperative Measurement of Serum MicroRNA-125b May Predict the Presence of Microvascular Invasion in Hepatocellular Carcinomas Patients.
A Preoperative Measurement of Serum MicroRNA-125b May Predict the Presence of Microvascular Invasion in Hepatocellular Carcinomas Patients.
复制标题
术前测量血清 MicroRNA-125b 可以预测肝细胞癌患者微血管侵袭的存在。
DOI：
10.1016/j.tranon.2016.03.002
复制
发表时间：
2016-06
影响因子：
5
通讯作者：
Wu J
中科院分区：
文献类型：
--
作者：
Liu M;Wang L;Zhu H;Rong W;Wu F;Liang S;Xu N;Wu J
高复发率仍然是影响肝细胞癌（HCC）患者肝切除术预后的主要问题。微血管侵犯（MVI）的存在被认为是导致术后复发的最重要的危险因素。我们之前的研究提示血清microRNA-125b （miR-125b）与MVI相关。本研究的目的是确定血清miR-125b是否可以作为一种生物标志物，可靠地预测术前微血管侵袭（MVI）。采用实时荧光定量PCR （quantitative real-time PCR, qRT-PCR）对108例HCC患者术前血清中的MiR-125b进行定量分析。我们的研究结果显示，MVI与术后HCC患者的无复发生存（RFS）相关；手术切缘宽度与MVI患者术后RFS相关，但与无MVI患者无关。多因素分析显示，miR-125b、肿瘤大小和AFP是该队列中与MVI相关的独立预测因素(P = 0.001，。001年,。003年,分别)。miR-125b的预测准确率概率为76.95%（特异性为51.32%，敏感性为87.50%），与结合AFP和肿瘤大小建立的分类器（概率为78.82%，特异性为65.63%，敏感性为84.21%）基本相当。结合肿瘤大小、AFP和miR-125b的ROC曲线面积为86.68%（特异性为72.37%，敏感性为84.38%）。我们的研究表明，血清miR-125b可用于HCC患者肝切除术前的MVI预测。因此，miR-125b可以潜在地指导个体化治疗，帮助HCC患者，无论有无MVI，从不同的手术入路中获益。
The high recurrence rate remains a major problem that strongly influenced the prognosis of hepatocellular carcinoma (HCC) patients who received hepatectomy. The presence of microvascular invasion (MVI) is regarded as the most important risk factor that contributes to the postoperative recurrence. Our previous study has hinted that serum microRNA-125b (miR-125b) was associated with MVI. The aim of the present study was to identify whether serum miR-125b can serve as a biomarker to reliably predict microvascular invasion (MVI) preoperatively. MiR-125b was quantified in 108 HCC patients’ serum before they received surgery by quantitative real-time PCR (qRT-PCR). Our results revealed that MVI was associated with relapse free survival (RFS) of postoperative HCC patients; surgical margin width was associated with postoperative RFS in MVI present patients, but not in the patients without MVI. Multivariate analysis revealed that miR-125b, tumor size and AFP were the independent predictive factors associated with MVI in this cohort (P = .001, .001, .003, respectively). The probability of the predictive accuracy of miR-125b was 76.95% (51.32% specificity and 87.50% sensitivity), which was almost equal to the classifier established by combination of AFP and tumor size (78.82% probability, 65.63% specificity and 84.21% sensitivity). Furthermore, the combination of tumor size, AFP and miR-125b yielded a ROC curve area of 86.68% (72.37% specificity and 84.38% sensitivity). Our study indicated that serum miR-125b can be used to predict MVI of HCC patients before they received hepatic resection. Therefore, miR-125b can potentially guide individualized treatment, which helps HCC patients, with or without MVI, to benefit from different surgical approach.